We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-9.98%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$6.17B
AUM Growth
-$1.61B
Cap. Flow
-$473M
Cap. Flow %
-7.66%
Top 10 Hldgs %
32.27%
Holding
171
New
12
Increased
33
Reduced
25
Closed
28

Top Buys

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$89.7M
2
PFE icon
Pfizer
PFE
+$66.9M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$65.8M
4
ARGX icon
argenx
ARGX
+$49.4M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$47.1M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$136M
2
BMY icon
Bristol-Myers Squibb
BMY
+$116M
3
HCA icon
HCA Healthcare
HCA
+$100M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$82.9M
5
SVA
Sinovac Biotech, Ltd
SVA
+$72.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.72%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTGN icon
76
VistaGen Therapeutics
VTGN
$9.73M
$16M 0.26%
430,309
– –
ILMN icon
77
Illumina
ILMN
$29.4B
$15.8M 0.26%
46,363
– –
HARP
78
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$15.1M 0.24%
303,951
+13,600
+5% +$705K
DBTX
79
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$15M 0.24%
4,945,192
– –
OMIC
80
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$14.5M 0.24%
76,693
+6,548
+9% +$1.52M
SYBX
81
DELISTED
Synlogic
SYBX
$14.5M 0.23%
402,000
– –
ERAS icon
82
Erasca
ERAS
$6.14B
$14.3M 0.23%
1,667,693
– –
CLDX icon
83
Celldex Therapeutics
CLDX
$2.81B
$13.8M 0.22%
406,100
– –
AMGN icon
84
Amgen
AMGN
$213B
$13.8M 0.22%
57,100
– –
ETNB
85
DELISTED
89bio
ETNB
$13.8M 0.22%
3,658,869
-70,573
-2% -$455K
BNR
86
Burning Rock Biotech
BNR
$96.9M
$13.5M 0.22%
145,240
– –
NXTC icon
87
NextCure
NXTC
$21.2M
$13.2M 0.21%
225,918
– –
LKFT
88
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
$12.9M 0.21%
208,225
-509,032
-71% -$31.2M
DHR.PRB
89
DELISTED
Danaher Corporation 5.00% Mandatory Convertible Preferred Stock, Series B
DHR.PRB
– –
0
– –
CMMB
90
Chemomab Therapeutics
CMMB
$10.6M
$12.4M 0.2%
644,544
– –
CRVS icon
91
Corvus Pharmaceuticals
CRVS
$1.11B
$11.4M 0.18%
6,943,654
– –
SGFY
92
DELISTED
Signify Health, Inc.
SGFY
$11.3M 0.18%
+620,700
New +$8.9M
TERN
93
DELISTED
Terns Pharmaceuticals
TERN
$11.3M 0.18%
3,791,204
– –
ORIC icon
94
Oric Pharmaceuticals
ORIC
$1.2B
$11.1M 0.18%
2,087,568
-250,006
-11% -$2.25M
LUNG icon
95
Pulmonx
LUNG
$53.6M
$10.8M 0.18%
435,000
– –
ALXO icon
96
ALX Oncology
ALXO
$265M
$10.5M 0.17%
621,700
+414,100
+199% +$7.07M
BLU
97
DELISTED
BELLUS Health Inc.
BLU
$10.1M 0.16%
1,454,800
– –
XBI icon
98
State Street SPDR S&P Biotech ETF
XBI
$10B
$10M 0.16%
111,800
-897,900
-89% -$82.9M
JBIO
99
Jade Biosciences
JBIO
$1.19B
$9.35M 0.15%
14,570
-736
-5% -$286K
DMRA
100
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.81B
$9M 0.15%
163,637
– –
2 3
4
5 6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q1 2022 Portfolio in Review

As of Q1 2022, OrbiMed held 171 positions worth $6.17B, down 21% from $7.78B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

OrbiMed withdrew a net $473M in Q1 2022, closing 28 positions and reducing 25 holdings. Its most notable exit was Merck, an estimated $136M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Industrials.

Against the trend, OrbiMed opened a new position in Biohaven Pharmaceutical Holding Company Ltd. worth $85.3M.

  • OrbiMed's largest Q1 2022 buy was Biohaven Pharmaceutical Holding Company Ltd.: 719,034 shares worth $85.3M.
  • OrbiMed added most to Pfizer in Q1 2022, an estimated $66.9M increase.
  • OrbiMed's biggest Q1 2022 reduction was Bristol-Myers Squibb, cutting an estimated $116M.
  • OrbiMed fully exited Merck in Q1 2022, selling an estimated $136M.
  • OrbiMed's ten largest holdings make up 32% of its $6.17B portfolio in Q1 2022.
  • OrbiMed opened 12 new positions and closed 28 in Q1 2022.
  • OrbiMed's portfolio value fell 21% quarter-over-quarter to $6.17B.

Based on OrbiMed's 13F filing for Q1 2022, filed 16 May 2022.